TARS
HealthcareTarsus Pharmaceuticals, Inc. · Biotechnology · $3B
What is Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic and dermatological conditions. Headquartered in Irvine, California, the company is building a pipeline centered on its lead compound, lotilaner, across multiple disease areas.
Tarsus generates revenue by advancing novel therapeutic candidates through clinical trials and into commercialization. Its lead program targets blepharitis caused by Demodex mite infestation — a common but underdiagnosed eye condition — as well as meibomian gland disease. Beyond eye care, the company is expanding its pipeline into dermatology with a rosacea candidate and into infectious disease with programs targeting Lyme disease prophylaxis and malaria reduction. The core platform leverages the active ingredient lotilaner across these distinct therapeutic areas.
Tarsus Pharmaceuticals was incorporated in 2016 and is headquartered in Irvine, California.
- TP-03: treatment for Demodex blepharitis and meibomian gland disease
- TP-04: investigational therapy for rosacea
- TP-05: prophylaxis candidate for Lyme disease and malaria reduction
- Lotilaner platform across eye care, dermatology, and infectious disease
Is TARS a Good Stock to Buy?
UQS Score rates TARS as Good overall, reflecting a pipeline-stage company with meaningful upside potential alongside real execution risk.
The Growth pillar stands out as the strongest element of TARS's profile, consistent with a company advancing a lead product through late-stage trials into a largely untapped patient population. The Risk and Valuation pillars both register as Good, suggesting the market has not yet priced in an extreme premium relative to the company's stage.
The Quality and Moat pillars both register as Weak — not unusual for a clinical-stage biopharma, but a signal that durable competitive advantages and financial self-sufficiency have not yet been established.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TARS pay dividends?
No — Tarsus Pharmaceuticals, Inc. does not currently pay a dividend.
Tarsus Pharmaceuticals does not currently pay a dividend. As a clinical-stage biopharmaceutical company, capital is directed toward research, clinical trials, and commercialization efforts rather than shareholder distributions. This is standard practice for companies at this stage of development, where reinvestment into the pipeline is the primary value-creation strategy.
When does TARS report earnings?
Tarsus Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
As a clinical-stage company, quarterly results tend to reflect pipeline progress, cash runway, and operating expenses rather than product revenue at scale. Investors typically focus on trial readouts and regulatory milestones alongside financial updates.
For the most recent quarter's results and upcoming reporting dates, visit Tarsus Pharmaceuticals' investor relations page directly.
TARS Price History
+93.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Tarsus Pharmaceuticals, Inc.?
Based on Tarsus Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TARS Long-term Outlook
The Strong Growth pillar suggests the market sees meaningful near-term catalysts tied to pipeline advancement and potential commercialization of TP-03. The Good Risk rating indicates the company's risk profile is manageable relative to sector peers, though clinical and regulatory uncertainty remains inherent at this stage. The Good Valuation pillar implies the current price does not appear to reflect runaway optimism, leaving room for the growth thesis to play out if key milestones are met.
Growth drivers
- Late-stage advancement of TP-03 into a large, underdiagnosed patient population
- Lotilaner platform expansion across multiple therapeutic categories
- Potential first-mover positioning in the Demodex blepharitis treatment market
Key risks
- Clinical trial failure or regulatory setback for lead pipeline candidates
- Cash burn and financing risk typical of pre-profitability biopharma companies
- Competitive entry from larger ophthalmic or dermatology-focused players
TARS vs Peers
Tarsus operates in a competitive biopharma landscape alongside other clinical-stage companies pursuing niche therapeutic opportunities.
Veradermics focuses on dermatological therapeutics, overlapping with Tarsus's rosacea and skin-adjacent pipeline ambitions.
Enliven is a clinical-stage oncology company, representing a different therapeutic focus but a similar stage of development and investor risk profile.
Structure Therapeutics pursues GPCR-targeted small molecule drugs, competing for clinical-stage biopharma investor attention rather than direct disease-area overlap.
Frequently Asked Questions
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for eye conditions, skin diseases, and infectious diseases. Its lead program targets blepharitis caused by Demodex mites, using the active compound lotilaner. The company is also advancing candidates for rosacea, Lyme disease prophylaxis, and malaria reduction.
Does TARS pay dividends?
No, Tarsus Pharmaceuticals does not currently pay a dividend. The company is in a clinical development phase and directs available capital toward advancing its pipeline rather than returning cash to shareholders. Dividend payments are not typical for companies at this stage.
When does TARS report earnings?
Tarsus Pharmaceuticals follows a standard quarterly earnings cadence for US-listed companies. For exact reporting dates and the most recent financial results, check the investor relations section of the Tarsus Pharmaceuticals website directly.
Is TARS a good stock to buy?
UQS Score rates TARS as Good overall. The Growth pillar is Strong, and both Risk and Valuation register as Good — a combination that may appeal to investors comfortable with clinical-stage risk. However, Weak Quality and Moat scores reflect the early-stage nature of the business. The full pillar breakdown is available to UQS Pro members.
Is TARS overvalued?
The UQS Valuation pillar for TARS is rated Good, suggesting the stock does not appear to be trading at an extreme premium relative to its stage and sector peers. That said, valuation for clinical-stage biotechs is inherently tied to pipeline outcomes, which carry binary risk.
How does TARS compare to its competitors?
Tarsus competes in the clinical-stage biopharma space alongside companies like Veradermics, Enliven Therapeutics, and Structure Therapeutics. What distinguishes Tarsus is its focus on a specific, underserved ophthalmic indication — Demodex blepharitis — and its multi-category lotilaner platform. UQS Pro members can view side-by-side score comparisons.
What is TARS's market cap bracket?
Tarsus Pharmaceuticals is classified as a mid-cap company. This places it in a segment of the market that often balances growth potential with somewhat more stability than micro- or small-cap peers, though clinical-stage risk remains the dominant factor for this company.
Who founded Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals was incorporated in 2016. Founding and leadership details are publicly available through the company's official website and SEC filings, which provide the most accurate and up-to-date information on its executive history.
Is TARS a long-term quality investment?
From a long-term quality perspective, TARS presents a mixed picture. The Strong Growth pillar points to meaningful pipeline momentum, while Weak Quality and Moat scores reflect the absence of established competitive advantages and consistent profitability. Long-term quality indicators improve as pipeline candidates reach commercialization. UQS Pro provides the full multi-pillar view.
What is the main competitive advantage of Tarsus Pharmaceuticals?
Tarsus's primary differentiator is its focus on Demodex blepharitis — a condition affecting a large patient population with limited approved treatment options. The lotilaner platform also offers potential for expansion across dermatology and infectious disease, giving the company multiple shots at building durable value from a single core compound.
What sector does TARS belong to?
Tarsus Pharmaceuticals operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its programs span ophthalmology, dermatology, and infectious disease, making it a multi-indication biopharma rather than a single-disease-focused company.
Is TARS a growth stock or value stock?
Based on its UQS profile, TARS leans toward the growth end of the spectrum. The Growth pillar is rated Strong, while the Valuation pillar is Good rather than deeply discounted — a profile more consistent with a growth-oriented clinical-stage biotech than a traditional value play.
Unlock Full TARS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare TARS side-by-side with sector peers
- ✓See Growth and Risk pillar drivers in depth
- ✓Track score changes as pipeline milestones develop
- ✓Full analyst-grade view available to Pro members
Pro Analysis
TARS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 55.0 | 16.7 | 37.0 | 100.0 | 72.0 | 72.0 | +0.2 |
| May 21, 2026 | 54.8 | 16.7 | 37.0 | 100.0 | 72.0 | 70.4 | -0.1 |
| May 18, 2026 | 54.9 | 16.7 | 37.0 | 100.0 | 72.0 | 71.3 | +0.1 |
| May 13, 2026 | 54.8 | 16.7 | 37.0 | 100.0 | 72.0 | 70.3 | -0.3 |
| May 11, 2026 | 55.1 | 16.7 | 37.0 | 100.0 | 72.0 | 72.4 | +1.9 |
| May 7, 2026 | 53.2 | 16.7 | 37.0 | 100.0 | 60.1 | 71.6 | 0.0 |
| May 3, 2026 | 53.2 | 16.7 | 37.0 | 100.0 | 60.1 | 71.9 | -0.2 |
| Apr 29, 2026 | 53.4 | 16.7 | 37.0 | 100.0 | 60.1 | 72.8 | +0.1 |
| Apr 26, 2026 | 53.3 | 16.7 | 37.0 | 100.0 | 60.1 | 72.7 | +0.3 |
| Apr 19, 2026 | 53.0 | 16.7 | 37.0 | 100.0 | 60.1 | 70.4 | +0.3 |
TARS — Pillar Breakdown
Quality
— 16.7/100 (25%)Tarsus Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Tarsus Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 72.0/100 (15%)Tarsus Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 72.0/100 (15%)Tarsus Pharmaceuticals, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 37/100 (25%)Tarsus Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TARS.
Score Composition
Financial Data
More Stock Analysis
How is the TARS UQS Score Calculated?
The UQS (Unified Quality Score) for Tarsus Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Tarsus Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Tarsus Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.